

RESEARCH

Open Access

Performance characteristics of biodistribution of 99m Tc-cefprozil for *in vivo* infection imaging

Mahmoud Hamdi Sanad^{1*} and EH Borai²

Abstract

Background: Cefprozil, an antibiotic used to treat bacterial infections, was labeled with 99m Tc. 99m Tc-cefprozil was prepared by adding 99m Tc to cefprozil in the presence of 50 µg SnCl₂ dihydrate at pH 4 and 30-minutes reaction time. The radiochemical yield and purity of 99m Tc-cefprozil were evaluated after species separation individually followed by subsequent quantification of the free and complexed species.

Methods: 4 mg of cefprozil was accurately weighed and transferred to an evacuated penicillin vial. Exactly 50 µg SnCl₂ solution was added and the pH of the mixture was adjusted to 4 using 0.1N HCl, then the volume of the mixture was adjusted to one ml with N₂-purged bidistilled water. One ml of freshly eluted 99m TcO₄⁻ (200- 400MBq) was added to the above mixture.

Results: The obtained maximum radiochemical yield was found to be $97.5\% \pm 0.8\%$. The 99m Tc-cefprozil complex was stable for 6 hrs. The biological distribution of 99m Tc-cefprozil was experimentally investigated in induced-infection mice, in the left thigh, using *Staphylococcus aureus*.

Conclusions: T/NT for 99m Tc-cefprozil was found to be 5.5 ± 0.12 at 2 hrs after intravenous injection, which was higher than that of the commercially available 99m Tc-ciprofloxacin followed by gradual decline. The abscess to normal muscle ratio indicated that 99m Tc-cefprozil could be used for infection imaging. Moreover, 99m Tc-cefprozil could efficiently differentiate between bacterial infection and sterile inflammation.

Keywords: Cefprozil; Ciprofloxacin; Technetium-99m; Infection; Inflammation

Background

Nuclear medicine scintigraphy (NMS) techniques are proving valuable in understanding the disease processes at molecular levels without the inconvenient invasive procedures, if a specific ligand is provided for a pathological process. The role of NMS in the diagnosis of infection and its discrimination from non-infective inflammatory processes and tumors at an early stage is clinically vital for appropriate management (Wouter et al. 2010; Sandip et al. 2009; David-Axel et al. 2006; Carrino et al. 2006). The radiolabeled leucocytes can be considered as gold standard for the identification of inflammatory foci in the intestine and bone tissues (Weiner 1990). The development of new radiopharmaceuticals that do not require the manipulation of blood and are able to differentiate between inflammatory

and infectious processes with high sensitivity and specificity is considered as the object of recent research. Therefore, other preparations such as 99m Tc-nanocolloid, 67 Ga-citrate, and 99m Tc or 111 In-labeled human polyclonal immunoglobulin are currently being tested (Buscombe et al. 1991). However, none of the preparations is capable of distinguishing between infections and inflammatory lesions in a clinically useful manner. Recently, a new proposal is based on the use of radiolabeled antibiotics. One of the most important radiopharmaceuticals which are now currently available for imaging infection, the antimicrobial agent ciprofloxacin labeled with 99m Tc, has probably shown significant benefits. The fundamental problems of 99m Tc-ciprofloxacin preparation discussed in the literature (McAfee et al. 1991; Akhtar et al. 2005, 2004; Nibbering et al. 2004; El-Ghany et al. 2007) are related to radiochemical purity as well as to the stability of the labeled complex. So, other antimicrobial agents such as levofloxacin (El-Ghany et al. 2005), pefloxacin (Motaleb 2007a, b),

* Correspondence: msanad74@yahoo.com

¹Labeled Compounds Department, Hot Labs Center, Atomic Energy Authority, P.O. Box 13759, Cairo, Egypt

Full list of author information is available at the end of the article

lomefloxacin (Motaleb 2007a, b), cefoprazone (Motaleb 2007a, b), cefuroxime (Yurt Lambrecht et al. 2008), rifampicin (Syed et al. 2010), and amoxicillin (Motaleb and Sanad 2012) were labeled with ^{99m}Tc to be used for imaging sites of infection and to overcome the drawback of ^{99m}Tc -ciprofloxacin (Kleisner et al. 2002; Yang et al. 2009). Cefprozil is a semi-synthetic broad-spectrum cephalosporin antibiotic. Cefprozil is a *cis* and *trans* isomeric mixture ($\geq 90\%$ *cis*). The chemical name of cefprozil is (6R,7R)-7-[(R)-2-amino-2-(*p*-hydroxyphenyl) acetamido]-8-oxo-3-propenyl-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-carboxylic acid (Petropoulos et al. 2009; Shaikh et al. 2008). Cefprozil has *in vitro* activity against a broad range of gram-positive and gram-negative bacteria. The bactericidal action of cefprozil results from inhibition of cell wall synthesis (Breier et al. 2002; Can 2011). In this paper, cefprozil was labeled with the most widely used imaging radionuclide, ^{99m}Tc . Factors affecting the labeling yield of ^{99m}Tc -cefprozil complex and biological distribution in inflammation bearing animals were studied in detail.

Experimental

Chemicals and materials

Cefprozil was purchased from Sigma-Aldrich Chemical Company (St. Louis, MO, USA); its structure is presented in Figure 1. All the other chemicals were purchased from Merck (Whitehouse Station, NJ, USA), and they were reactive grade reagents. The water used is purged with nitrogen gas to give deoxygenated bidistilled water.

Apparatus

Well-type γ -scintillation counter: Scalar Ratemeter SR7 (Nuclear Enterprises Ltd., USA); pH meter: model 601, a digital ion analyzer (Orion Research, Jacksonville, FL, USA); ionization chamber: model CRC-15R (Capintec, Ramsey, NJ, USA); precision electronic balance: model HA 120 (MAD Company Ltd., Japan); stirring hot plate: model 210T Thrmix (Fisher, Waltham, MA, USA); electrophoresis apparatus: E.C. Corporation (Albany, OR, USA)

Labeling of cefprozil

Cefprozil (4 mg) was accurately weighed and transferred to an evacuated penicillin vial. Exactly 50- μg SnCl_2 solution was added, and the pH of the mixture was adjusted to 4 using 0.1 N HCl; then, the volume of the mixture was adjusted to 1 ml with N_2 -purged bidistilled water. One millimeter of freshly eluted $^{99m}\text{TcO}_4^-$ (200 to 400 MBq) was added to the above mixture. The reaction mixture was vigorously shaken and allowed to react at room temperature for a sufficient time to complete the reaction. This experiment was conducted to study the different factors that affect the labeling yield such as tin content (as $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$), substrate content, pH of the reaction medium, and reaction time. For labeling process, trials were performed for each factor under investigation to obtain the optimum value. The experiment was repeated with all factors kept at optimum values except the factor under study, until the overall optimal conditions are achieved.

Separation methods and recovery of ^{99m}Tc -cefprozil complex

Paper chromatography

The radiochemical yield of ^{99m}Tc -cefprozil was determined by paper chromatography, in which the reaction product was spotted on ascending paper chromatography strips (10×1.5 cm). Free $^{99m}\text{TcO}_4^-$ in the preparation was determined using acetone as the mobile phase. Reduced hydrolyzed technetium was determined by using ethanol/water/ammonium hydroxide mixture (2:5:1) or 5 N NaOH as the mobile phase. After complete development, the strips were dried, cut into 0.5-cm pieces, and counted in a well-type γ -scintillation counter.

Electrophoresis conditions

Electrophoresis was done with EC-3000 p-series programmable power and chamber supply units (E.C. Apparatus Corporation) using cellulose acetate strips. The strips were moistened with 0.05 M phosphate buffer pH 7.2 ± 0.2 and then were introduced in the chamber. The samples (5 μl) were applied at a distance of 10 cm




Figure 1 The chemical structure of cefprozil.

from the cathode. The radioactivity values were evaluated at an applied voltage of 300 V and standing time of 1.5 h. The developed strips were dried and cut into 1-cm segments and counted by a well-type NaI scintillation counter. The radiochemical yield was calculated as the ratio of the radioactivity of the labeled product to the total radioactivity.

HPLC analysis

A simple, short, rapid, sensitive, and robust reversed phase high-performance liquid chromatographic (HPLC) method was developed and validated to measure the amount of cefprozil in dissolution profile. An isocratic elution of filtered sample was performed on cosmosil RP18 LiChrosorb column (250 mm × 4 mm, 5 µm, Merck) using water/acetonitrile solution (90:10, v/v) as mobile phase and at a UV detection at 200 nm. The mobile phase was delivered at a flow of 1.0 ml/min and at a maintained column temperature at 50°C, and quantification was achieved with reference to the external standards (Asikoglu et al. 2000). Then, fractions of 1.0 ml were collected separately using a fraction collector up to 15 ml and counted in a well-type γ-scintillation counter.

Stability of ^{99m}Tc -cefprozil in human serum

The stability of ^{99m}Tc -cefprozil was studied *in vitro* by mixing 1.8 ml of normal human serum and 0.2 ml of ^{99m}Tc -cefprozil and incubated at 37°C for 24 h. Exactly 0.2-ml aliquots were withdrawn during the incubation at different time intervals up to 24 h and subjected to paper chromatography for the determination of the percentage of ^{99m}Tc -cefprozil, reduced hydrolyzed technetium, and free pertechnetate.

Induction of infectious foci

A single clinical isolation of *Staphylococcus aureus* (Boyd 1986) from biological samples was used to produce focal infection. Individual colonies were diluted in order to obtain turbid suspension. Groups of five mice, weighing approximately 25 g each, were injected with 200 µl of the above suspension in the left thigh muscle. Twenty-four hours was required to get gross swelling in the infected thighs.

Induction of non-infected inflammation

Sterile inflammation was induced by injecting 200 µl of turpentine oil (Robbins 1984), which was sterilized by autoclaving at 121°C for 20 min, intramuscularly in the left lateral thigh muscle of the Albino mice. Two days later, swelling appeared.

In vitro binding of ^{99m}Tc -cefprozil to bacteria

Binding of ^{99m}Tc -cefprozil to *S. aureus* bacteria was assessed by the method described elsewhere (Welling et al.

2000). Briefly, 0.1 ml of sodium phosphate buffer containing about 5 MBq of ^{99m}Tc -cefprozil was transferred to a test tube. Exactly 0.8 ml of 50% (v/v) of 0.01 M acetic acid in phosphate buffer containing approximately 1 × 10⁸ viable bacteria was added. The mixture was incubated for 1 h at 4°C and then centrifuged for 5 min at 2,000 rpm at 4°C. Simultaneously, the incubation was performed in the presence of an excess of unlabeled cefprozil (10-, 50-, 100-fold). The supernatant was removed, and the bacterial pellet was gently resuspended in 1.0 ml of ice-cooled phosphate buffer and recentrifuged. The supernatant was removed, and the radioactivity in the bacterial pellet was determined by a γ-counter. The radioactivity related to the bacteria was expressed in percentages of the added ^{99m}Tc activity bound to viable bacteria in regard to the total ^{99m}Tc activity.

Animal studies

The study was approved by the animal ethics committee of the Labeled Compound Department and was in accordance with the guidelines set out by the Egyptian Atomic Energy Authority. For the infection model, the animals, Swiss Albino mice (25 to 30 g), were intravenously injected with 100 µl (100 to 150 MBq) of sterile ^{99m}Tc -cefprozil, adjusted to physiological pH via the tail vein, and kept alive in metabolic cage for different intervals of time under normal conditions. For quantitative determination of organ distribution, five mice were used for each experiment, and the mice were sacrificed at different times post-injection. Samples of fresh blood, bone, and muscles were collected in pre-weighed vials and counted. The different organs were removed, counted, and compared to a standard solution of the labeled cefprozil. The average percent values of the administrated dose/organ were calculated. The blood, bone, and muscles were assumed to be 7%, 10%, and 40%, respectively, of the total body weight (Motaleb 2001). Corrections were made for background radiation and physical decay during experiment. Both target and non-target thighs were dissected and counted. Differences in the data were evaluated with Student *t* test. Results for *p* using the two-tailed test were reported, and all the results are given as mean ± SEM. The level of significance was set at *P* < 0.05.

Results and discussion

Separation characteristics

In case of ascending paper chromatographic method, acetone was used as the developing solvent, free $^{99m}\text{TcO}_4^-$ moved with the solvent front ($R_f = 1$), while ^{99m}Tc -cefprozil and reduced hydrolyzed technetium remained at the point of spotting. In the case of ascending paper chromatographic method, the mixture was used as the developing solvent; reduced hydrolyzed technetium remains at the




Figure 2 HPLC radiochromatogram of ^{99m}Tc -cefprozil complex.

origin ($R_f = 0$), while the other species migrate with the solvent front ($R_f = 1$). The radiochemical purity was determined by subtracting the sum of the percentage of reduced hydrolyzed technetium and free pertechnetate from 100%.

The paper electrophoresis pattern revealed that the ^{99m}Tc -cefprozil complex moved towards the anode, indicating the anionic nature of this complex. Under similar condition, $^{99m}\text{TcO}_4^-$ moved considerably toward the anode, suggesting that it has a completely ionized negative charge.

An HPLC chromatogram was presented in Figure 2 and showed two peaks, one at fraction no. 3.25, which corresponds to $^{99m}\text{TcO}_4^-$, while the second peak was collected at fraction no. 7.3 for ^{99m}Tc -cefprozil which was found to coincide with the UV signal.

Factors affecting the labeling yield

Effect of ligand concentration

As shown in Figure 3, relatively low labeling yield of ^{99m}Tc -cefprozil, $75.3\% \pm 0.4\%$, was obtained at low ligand concentration (1 mg). This low labeling yields was attributed to the ligand concentrations being insufficient to form the complex with all of the reduced technetium-99m, while the percentage of the colloid was high $14.9\% \pm 0.5\%$. Increasing the ligand concentration led to higher labeling yield, and the maximum yield ($97.5\% \pm 0.8\%$) was achieved at 4 mg. By increasing the ligand concentration over the optimum values, the labeling yield remained stable.

Effect of $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$ amount

The effect of the amount of stannous chloride was summarized in Figure 4. The data showed that the radiochemical




Figure 3 Effect of cefprozil amount on the labeling yield of ^{99m}Tc -cefprozil complex. Conditions: 1 to 10 mg of cefprozil, 50 μg Sn (II), pH 4, and 30-min reaction time; $n = 3$.




Figure 4 Effect of Sn (II) amount on the labeling yield of ^{99m}Tc -cefprozil complex. Conditions: 4 mg cefprozil, 25 to 200 μg Sn (II), pH 4, and 30-min reaction time; $n = 3$.

yield was dependent on the amount of $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$ present in the reaction mixture. At 25 μg $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$, the labeling yield of ^{99m}Tc -cefprozil was $65.6\% \pm 0.71\%$ due to insufficient $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$ concentration to reduce all pertechnetate, so the percentage of $^{99m}\text{TcO}_4^-$ was relatively high (Guarna et al. 2001). The labeling yield was significantly increased by increasing the amount of $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$ from 25 to 200. At 50 μg (optimum content), the maximum labeling yield of $97.5\% \pm 0.8\%$ was obtained. By increasing the amount of $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$ above the optimum concentration value, the labeling yield decreased gradually due to the conversion of the excess $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$ to colloid and reached to $55.4\% \pm 0.82\%$ at 200 μg $\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$ (Seung et al. 2002).

Effect of pH of the reaction mixture

As shown in Figure 5, at pH 1 the labeling yield of ^{99m}Tc -cefprozil complex was relatively low (50%). The yield increased with increasing pH of the reaction mixture, reaching the maximum labeling yield of $97.5\% \pm 0.8\%$ at pH 4. By increasing the pH greater than 4, the labeling yield decreased again to 62.8% at pH 6, at which the colloid impurity percentage becomes high ($32.7\% \pm 0.3\%$) (Motaleb et al. 2012, 2011).

Effect of reaction time

Figure 6 shows the effect of incubation time on the radiochemical purity of the ^{99m}Tc -cefprozil complex. At 1-min post labeling, the radiochemical purity reached to




Figure 5 Effect of pH on the labeling yield of ^{99m}Tc -cefprozil complex. Conditions: 4 mg cefprozil, 50 μg Sn (II), pH 1 to 6, and 30-min reaction time; $n = 3$.




Figure 6 Effect of reaction time on the labeling yield of ^{99m}Tc -cefprozil complex. Conditions: 4 mg cefprozil, 50 μg Sn (II), pH = 4, 1- to 120-min reaction time; $n = 3$.

$80.6\% \pm 0.7\%$, which increased with time until reaching its maximum value of $97.5\% \pm 0.8\%$ at 30 min. The radiochemical purity remains stable for up to 2 h (Ibrahim and Sanad 2013; Sanad and Ibrahim 2013).

Stability test

As shown in Figure 7, the *in vitro* stability of ^{99m}Tc -cefprozil was studied in order to determine the suitable time for injection to avoid the formation of the undesired products that result from the decomposition of the complex. These undesired radioactive products might be accumulated in non-target organs. The results of the stability test showed that the ^{99m}Tc -cefprozil is stable for 24 h at 37°C

which resulted in a small release of radioactivity of $17.0\% \pm 0.3\%$ ($n = 3$ experiments) from the ^{99m}Tc -cefprozil, as determined by paper chromatography.

In vitro binding studies

In vitro binding studies revealed that the binding of ^{99m}Tc -cefprozil to *S. aureus* bacteria was similar to that of ^{99m}Tc -ciprofloxacin, where the binding of ^{99m}Tc -cefprozil was in the range from 42% to 73% ($n = 5$), while the binding of ^{99m}Tc -ciprofloxacin was in the range from 40% to 65% ($n = 3$). The varying amounts of cefprozil added (10- to 100-fold) showed significant decrease in the binding of ^{99m}Tc -cefprozil to living bacteria, indicating




Figure 7 In vitro stability of ^{99m}Tc - cefprozil in normal serum at optimum condition.

Table 1 Biodistribution of 99m Tc-cefprozil in *Staphylococcus aureus* and turpentine oil-inflamed mice at different time intervals

Organs and body fluids	Percentage of injected dose/organs at different time intervals (h)							
	Turpentine oil				<i>S. aureus</i>			
	15 min	30 min	2 h	4 h	15 min	30 min	2 h	4 h
Inflamed muscle	0.90 ± 0.01	1.11 ± 0.02	1.20 ± 0.03	0.90 ± 0.02	0.95 ± 0.01	1.15 ± 0.01	1.21 ± 0.02	1.36 ± 0.01
Normal muscle	0.63 ± 0.02	0.37 ± 0.01	0.33 ± 0.01	0.45 ± 0.01	0.38 ± 0.01	0.26 ± 0.02	0.22 ± 0.01	0.37 ± 0.02
Blood	15.7 ± 0.21	9.8 ± 0.13	2.90 ± 0.21	1.50 ± 0.21	12.5 ± 0.13	8.64 ± 0.21	2.5 ± 0.12	1.1 ± 0.12
Kidneys	11.15 ± 0.63	20.55 ± 0.31	10.42 ± 0.12	9.45 ± 0.23	13.7 ± 0.14	17.9 ± 0.33	11.2 ± 0.14	8.25 ± 0.41
Liver	12 ± 0.11	10.22 ± 0.11	8.24 ± 0.11	5.75 ± 0.21	15.33 ± 0.11	11.42 ± 0.11	7.8 ± 0.11	6.9 ± 0.11
Spleen	5.1 ± 0.11	3.0 ± 0.11	2.7 ± 0.12	1.9 ± 0.21	4.4 ± 0.21	3.8 ± 0.12	3.1 ± 0.21	2.5 ± 0.13
Intestine	8.72 ± 0.11	6.12 ± 0.11	5.26 ± 0.13	3.31 ± 0.21	5.37 ± 0.12	4.6 ± 0.13	3.1 ± 0.21	2.12 ± 0.11
Stomach	1.12 ± 0.11	1.28 ± 0.11	1.9 ± 0.01	1.33 ± 0.01	1.43 ± 0.01	2.1 ± 0.02	1.8 ± 0.02	1.12 ± 0.06
Lungs	1.23 ± 0.12	1.5 ± 0.13	1.48 ± 0.11	1.37 ± 0.02	2.1 ± 0.01	1.7 ± 0.11	1.2 ± 0.02	1.4 ± 0.02
Heart	2.1 ± 0.21	1.61 ± 0.01	1.1 ± 0.11	1.2 ± 0.12	1.8 ± 0.11	1.2 ± 0.01	1.6 ± 0.11	1.5 ± 0.02
Bone	2.2 ± 0.12	2.16 ± 0.21	2.13 ± 0.32	2.3 ± 0.13	1.94 ± 0.31	1.45 ± 0.03	0.9 ± 0.02	1.52 ± 0.13
Urine	9.23 ± 0.4	12.6 ± 0.4	21.3 ± 0.63	30.5 ± 0.83	10.5 ± 0.14	13.15 ± 1.14	28.86 ± 0.84	34.54 ± 0.15
T/NT	1.43 ± 0.01	3.0 ± 0.04	3.6 ± 0.11	2.0 ± 0.01	2.5 ± 0.01	4.4 ± 0.16	5.5 ± 0.12	3.70 ± 0.03

that the 99m Tc-cefprozil complex is a specific agent for bacterial cells (Figure 8).

Biodistribution of 99m Tc-cefprozil

Table 1 shows the biodistribution of 99m Tc-cefprozil in important body organs and fluids. 99m Tc-cefprozil was removed from the circulation mainly through the kidneys and urine (approximately 42.79% injected dose, ID, at 4 h after injection of the tracer). The liver uptake decreased markedly with time from 15.33% at 15 min to 6.9% at 4 h. The mice with infectious lesions injected

with 99m Tc-cefprozil showed a mean target-to-non-target (T/NT) ratio equal to 5.5 ± 0.12 which is greater than that of 99m Tc-ciprofloxacin (T/NT = 3.8 ± 0.8) (Ibrahim et al. 2011). The accumulation of activity at the site of infection was maximized at 2 h after intravenous injection then slightly decreased with time until T/NT was equal to 3.70 ± 0.03 at 4 h post injection. During the first 2 h, the radioactivity level in the blood was higher than that in the inflammation-induced area. This means that the images of 99m Tc-cefprozil by gamma camera will be affected by the blood pool images that arise from the




Figure 8 *In vitro* binding of 99m Tc-cefprozil to *Staphylococcus aureus*.




Figure 9 T/NT of ^{99m}Tc-cefprozil complex in different inflammation models at different post injection times.

high blood activity. Therefore, it is recommended to obtain more specific images for ^{99m}Tc-cefprozil after 4 h (Figure 9).

Conclusion

^{99m}Tc-cefprozil was labeled easily using 50 µg SnCl₂·2H₂O as a reducing agent at pH 4 and 30-min reaction time with high labeling yield of 97.5% ± 0.8%. The ^{99m}Tc-cefprozil complex was stable up to 6 h, which shows high stability time in comparison to ciprofloxacin. Based on the data obtained from the biodistribution of ^{99m}Tc-cefprozil, it can be stated that there is a significant difference in the percentage uptake of ^{99m}Tc-cefprozil in the muscle injected with *S. aureus* and turpentine oil, which indicated that ^{99m}Tc-cefprozil is considered as a specific agent and could distinguish between bacterial infection and sterile inflammation. This result was supported by the data from *in vitro* binding of ^{99m}Tc-cefprozil with bacteria.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

EHB Make the analytical parts. MHS makes the rest of manuscript. Both authors read and approved the final manuscript.

Author details

¹Labeled Compounds Department, Hot Labs Center, Atomic Energy Authority, P.O. Box 13759, Cairo, Egypt. ²Analytical Chemistry Department, Hot Labs Center, Atomic Energy Authority, P.O. Box 13759, Cairo, Egypt.

Received: 21 May 2013 Accepted: 3 February 2014

Published online: 12 June 2014

References

- Akhtar MS, Iqbal J, Khan MA, et al. (2004) Investigation of four ^{99m}Tc-labeled bacteriophages for infection-specific imaging. *J Nucl Med* 45:849–856
- Akhtar MS, Qaisar A, Irfanullah J, et al. (2005) Antimicrobial peptide ^{99m}Tc-ubiquicidin 29–41 as human infection-imaging agent: clinical trial. *J Nucl Med* 46:567–573
- Asikoglu M, Yurt F, Cagliyan O, Unak P, Ozkilic H (2000) Detecting inflammation with 131I-labeled ornidazole. *Appl Radiat Isot* 53(3):411–413
- Boyd RE (1986) Technetium generators: status and prospects. *Nucl Spectrum* 2:18–25
- Breier AR, Garcia CV, Oppe TP, Steppe M, Schapoval EES (2002) Microbiological assay for azithromycin in pharmaceutical formulations. *J Pharm Biomed Anal* 29(5):957–961
- Buscombe JR, Miller RF, Lui D, et al. (1991) Combined Gallium-67-citrate and ^{99m}Tc-human immunoglobulin imaging in human immunodeficiency virus-positive patients with fever of unknown origin. *Nucl Med Commun* 12:583–592
- Can NO (2011) HPLC determination of cefprozil in tablets using monolithic C₁₈ silica columns. *J Sep Sci* 34:2223–2231
- Carrino JA, Blum J, Parellada JA, Schweitzer ME, Morrison WB (2006) MRI of bone marrow edema-like signal in the pathogenesis of subchondral cysts. *Osteoarthritis Cartilage* 10:1081–1085
- David-Axel L, Laureline B, Patrick M, Kasia B, Julien M, Yannick O, Marina G, Catherine R, Neal O, Sophie B, Charles RGG, Howard LW, Samia JK, Jean-Paul S (2006) Serial blood T cell repertoire alterations in multiple sclerosis patients: correlation with clinical and MRI parameters. *J Neuroimmunol* 177:151–160
- El-Ghany EA, El-Kolaly MT, Amine AM, El-Sayed AS, Abdel-Gelil F (2005) Synthesis of ^{99m}Tc-pefloxacin: a new targeting agent for infectious foci. *Radioanal Nucl Chem* 266(1):131–139
- El-Ghany EA, Amine AM, El-Kawy OA, Magdy A (2007) Technetium-99m labeling and freeze-dried kit formulation of levofloxacin (L-Flox): a novel agent for detecting sites of infection. *J Label Compd Radiopharm* 50(1):25–31
- Guarna A, Menchi G, Berti G, Cini N, Bottocettini A, Raspanti S, Politi A, Pupi A (2001) Molecular recognition of DNA by small molecules. *Bioorg Med Chem* 9:2215–2235
- Ibrahim IT, Sanad MH (2013) Radiolabeling and biological evaluation of losartan as a possible cardiac imaging agent. *Radiochemistry* 55(3):336–340
- Ibrahim T, El-Tawoosy M, Talaat HM (2011) Labeling of tannic acid with technetium-99m for diagnosis of stomach ulcer. *Int Scholarly Res Network Pharmaceutics* 5:42–47
- Kleisner I, Komarek P, Komarkova I, Konopkova M (2002) A new technique of ^{99m}Tc-ciprofloxacin kit preparation. *Nuklearmedizin* 41:224–229
- Mcafee JG, Gagne GG, Subramanian, et al. (1991) The localization of indium-111-leukocytes, gallium-67-polyclonal IgG and other radioactive agents in acute focal inflammatory lesions. *J Nucl Med* 32:2126–2131
- Motaleb MA (2001) Synthesis and evaluation of some ^{99m}Tc- complexes; applied in nuclear medicine, Ph.D. Thesis, Faculty of Science, Ain-Shams University, Cairo, Egypt
- Motaleb MA (2007a) Preparation and biodistribution of ^{99m}Tc-lomefloxacin and ^{99m}Tc-ofloxacin complexes. *Radioanal Nucl Chem* 272(1):95–99
- Motaleb MA (2007b) Preparation of ^{99m}Tc-cefoperazone complex, a novel agent for detecting sites of infection. *J Radioanal Nucl Chem* 272(1):167–171

- Motaleb MA, Sanad MH (2012) Preparation and quality control of ^{99m}Tc -6-[2-amino- 2-(4-hydroxyphenyl)-acetyl]amino]-3,3-dimethyl- 7-oxo-4-thia- 1-azabicyclo-heptane- 2-carboxylic acid complex as a model for detecting sites of infection. *Arab J Nucl Sci Appl* 45(3):71–78
- Motaleb MA, Moustapha ME, Ibrahim IT (2011) Synthesis and biological evaluation of ^{125}I -nebivolol as a potential cardioselective agent for imaging β_1 -adrenoceptors. *J Radioanal Nucl Chem.* doi:10.1007/s10967-011-1069-z
- Motaleb MA, Abdallah HEM, Atef M (2012) Synthesis and evaluation of ^{99m}Tc -NIDA and ^{99m}Tc -DMIDA complexes for hepatobiliary imaging. *J. Radiochmestry* 54(5):501–505
- Nibbering PH, Welling MM, Paulusma-Annema A, et al. (2004) ^{99m}Tc -Labeled UBI 29-41 peptide for monitoring the efficacy of antibacterial agents in mice infected with *staphylococcus aureus*. *J. Nucl Med* 45:321
- Petropoulos AD, Kouvela EC, Starosta AL, Wilson DN, Dinos GP, Kalpaxis DL (2009) Time-resolved binding of azithromycin to Escherichia coli ribosomes. *J Mol Biol* 385:1179–1192
- Rabbins PJ (1984) Chromatography of technetium-99m radiopharmaceuticals, a practical guide. Society of Nuclear Medicine, New York, NY, USA
- Sanad MH, Ibrahim IT (2013) Radiodiagnosis of peptic ulcer with technetium-99m pantoprazole. *J. Radiochemistry* 55(3):341–345
- Sandip B, Timothy C, Sihamak M, Hongming Z, Drew AT, Abass A (2009) Positron emission tomography as a diagnostic tool in infection: present role and future possibilities. *Semin Nucl Med* 1:36–51
- Seung JO, Jin SR, Joong WS, Eun JY, Hyun JH, et al. (2002) Synthesis of ^{99m}Tc -ciprofloxacin by different methods and its biodistribution. *J Appl Radiat Isot* 57:193–200
- Shaikh KA, Patil SD, Devkhile AB (2008) Development and validation of a reversed-phase HPLC method for simultaneous estimation of ambroxol hydrochloride and azithromycin in tablet dosage form. *J Pharm Biomed Anal* 48(5):1481–1484
- Syed QS, Aakif UK, Muhammad RK (2010) Radiosynthesis and biodistribution of ^{99m}Tc -rifampicin: a novel radiotracer for *in-vivo* infection imaging. *J Appl Radiat Isot* 68(12):2255–2260
- Weiner R (1990) The role of transferring and other receptors in the mechanism of Ga67 localization. *Int J Rad Appl Instrum B* 17:141–149
- Welling MM, Paulusma-Annema A, Balter HS, Pauwels EKJ, Nibbering PH (2000) Technetium-99m labelled antimicrobial peptides discriminate between bacterial infections and sterile inflammations. *Eur J Nucl Med* 27(3):292–301
- Wouter B, Chantal PB, Otto CB, Martin G, Wim JGO (2010) PET and SPECT in osteomyelitis and prosthetic bone and joint infections: a systematic review. *Semin Nucl Med* 40:3–15
- Yang ZY, Wang L, Tang X (2009) Determination of azithromycin by ion-pair HPLC with UV detection. *J Pharm Biomed Anal* 49(3):811–815
- Yurt Lambrecht F, Durkan K, Unak P (2008) Preparation, quality control and stability of $99m\text{Tc}$ -cefuroxime axetil. *J Radioanal Nucl Chem* 275(1):161–164

doi:10.1186/s40543-014-0032-3

Cite this article as: Sanad and Borai: Performance characteristics of biodistribution of ^{99m}Tc -cefprozil for *in vivo* infection imaging. *Journal of Analytical Science and Technology* 2014 **5**:32.

Submit your manuscript to a SpringerOpen® journal and benefit from:

- Convenient online submission
- Rigorous peer review
- Immediate publication on acceptance
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright to your article

Submit your next manuscript at ► springeropen.com